• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Landmark Outcomes Study Shows That Repatha ® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues
Repatha Significantly Reduces Risk of Hard Major Adverse Cardiovascular Events by 20 Percent Risks of Heart Attack, Stroke and Coronary Revascularization Were Nominally Reduced by 27 Percent, 21 Percent and 22 Percent, Respectively Patients in Study had History of Heart Attack, Stroke or Symptomatic Peripheral Arterial Disease and Were Treated With Optimized Statin Therapy Amgen to Offer Innovative Refund Contracts in the U.S. Detailed Results Simultaneously Published in the New England Journal of Medicine and Presented at the American College of Cardiology 66th Annual Scientific Session THOUSAND OAKS, Calif.,...
Source: Amgen News Release - March 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news